Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 4
1999 3
2000 3
2001 14
2002 32
2003 54
2004 45
2005 46
2006 30
2007 21
2008 8
2009 10
2010 8
2011 6
2012 6
2013 8
2014 4
2015 1
2016 2
2017 2
2018 1
2021 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

297 results

Results by year

Filters applied: . Clear all
Page 1
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Evans HC, Perry CM, Faulds D. Evans HC, et al. Drugs. 2004;64(6):649-78. doi: 10.2165/00003495-200464060-00010. Drugs. 2004. PMID: 15018597 Review.
After oral administration ximelagatran is rapidly bioconverted to melagatran. Melagatran inactivates both circulating and clot-bound thrombin by binding to the thrombin active site, thus, inhibiting platelet activation and/or aggregation and reducing fibrinolysis ti …
After oral administration ximelagatran is rapidly bioconverted to melagatran. Melagatran inactivates both circulating and clot …
New anticoagulants.
Bauer KA. Bauer KA. Hematology Am Soc Hematol Educ Program. 2006:450-6. doi: 10.1182/asheducation-2006.1.450. Hematology Am Soc Hematol Educ Program. 2006. PMID: 17124098 Review.
Ximelagatran, an oral prodrug of the direct thrombin inhibitor melagatran, showed efficacy in the prevention and treatment of venous thromboembolism as well as stroke prevention in patients with atrial fibrillation. ...
Ximelagatran, an oral prodrug of the direct thrombin inhibitor melagatran, showed efficacy in the prevention and treatment of venous …
Ximelagatran in orthopaedic surgery.
Eriksson B. Eriksson B. Pathophysiol Haemost Thromb. 2005;34 Suppl 1:10-7. doi: 10.1159/000083079. Pathophysiol Haemost Thromb. 2005. PMID: 15812199 Free article. Review.
Based on the results of METHRO II and III, the EXPRESS study evaluated the efficacy and bleeding profile of s.c. melagatran 2 mg immediately before surgery, followed by s.c. melagatran 3 mg on the evening of the day of surgery and then ximelagatran 24 mg twice daily …
Based on the results of METHRO II and III, the EXPRESS study evaluated the efficacy and bleeding profile of s.c. melagatran 2 mg imme …
The direct thrombin inhibitor melagatran/ximelagatran.
Brighton TA. Brighton TA. Med J Aust. 2004 Oct 18;181(8):432-7. doi: 10.5694/j.1326-5377.2004.tb06367.x. Med J Aust. 2004. PMID: 15487959 Review.
Melagatran is a synthetic, small-peptide direct thrombin inhibitor with anticoagulant activity. Ximelagatran, an oral prodrug, undergoes rapid enzymatic conversion to melagatran. Melagatran has rapid onset of action, fixed twice-daily dosing, stable absorptio …
Melagatran is a synthetic, small-peptide direct thrombin inhibitor with anticoagulant activity. Ximelagatran, an oral prodrug, underg …
Ximelagatran (AstraZeneca).
Hopfner R. Hopfner R. Curr Opin Investig Drugs. 2002 Feb;3(2):246-51. Curr Opin Investig Drugs. 2002. PMID: 12020054 Review.
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the potential prevention and treatment of venous thromboembolism (VTE) in hip and knee replacement, for prevention of stroke in atrialfibrillation (A …
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the poten …
Direct thrombin inhibitors.
Kaplan KL, Francis CW. Kaplan KL, et al. Semin Hematol. 2002 Jul;39(3):187-96. doi: 10.1053/shem.2002.34092. Semin Hematol. 2002. PMID: 12124681 Review.
There are three direct thrombin inhibitors approved for clinical use at present (lepirudin, bivalirudin, argatroban) and another in advanced clinical testing (melagatran/ximelagatran). The chemical structure, kinetics of thrombin inhibition, pharmacokinetics, and clinical …
There are three direct thrombin inhibitors approved for clinical use at present (lepirudin, bivalirudin, argatroban) and another in advanced …
Anticoagulant-related skin reactions.
Jörg I, Fenyvesi T, Harenberg J. Jörg I, et al. Expert Opin Drug Saf. 2002 Sep;1(3):287-94. doi: 10.1517/14740338.1.3.287. Expert Opin Drug Saf. 2002. PMID: 12904144 Review.
In the future, anticoagulant strategies may include direct synthetic thrombin inhibitors (argatroban and melagatran/ximelagatran) and the Factor Xa inhibitor, pentasaccharide (fondaparinux)....
In the future, anticoagulant strategies may include direct synthetic thrombin inhibitors (argatroban and melagatran/ximelagatran) and …
Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Wolzt M, Sarich TS, Eriksson UG. Wolzt M, et al. Semin Vasc Med. 2005 Aug;5(3):254-8. doi: 10.1055/s-2005-916164. Semin Vasc Med. 2005. PMID: 16123912 Review.
In contrast, ximelagatran has a low potential for pharmacokinetic drug:drug and food interactions. There is no significant metabolism of melagatran, and the main route of elimination of melagatran is renal excretion that appears to occur via glomerular filtration. . …
In contrast, ximelagatran has a low potential for pharmacokinetic drug:drug and food interactions. There is no significant metabolism of …
Ximelagatran.
Choudhury A, Goyal D, Lip GY. Choudhury A, et al. Drugs Today (Barc). 2006 Jan;42(1):3-19. doi: 10.1358/dot.2006.42.1.893611. Drugs Today (Barc). 2006. PMID: 16511607 Review.
Despite the significant advances over the last 50 years with regard to anticoagulant therapy, warfarin remains the definitive standard for the long-term prevention of thromboembolic events in at-risk patients, except those with acute coronary syndromes, in which antiplatelets are …
Despite the significant advances over the last 50 years with regard to anticoagulant therapy, warfarin remains the definitive standard for t …
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Eriksson BI. Eriksson BI. Thromb Res. 2003 Jul 15;109 Suppl 1:S23-9. doi: 10.1016/s0049-3848(03)00248-2. Thromb Res. 2003. PMID: 12818631 Review.
The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its active form melagatran, which also can be administered subcutaneously (s.c.). Two large-scale clinical trials (MElagatran for THRombin inhibi …
The oral direct thrombin inhibitor (oral DTI) ximelagatran (Exanta, AstraZeneca) is rapidly absorbed and bioconverted to its active form …
297 results